Outcomes of Dexamethasone Implant Treatment in Patients with Diabetic Macula Edema Anatomically Unresponsive to Intravitreal Bevacizumab Treatment: Early Switch to Dexamethasone Study
Retina-Vitreus, cilt.31, sa.1, ss.39-43, 2022 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.37845/ret.vit.2022.31.7
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE
- Sayfa Sayıları: ss.39-43
- Anahtar Kelimeler: Bevacizumab, Dexamethasone, Diabetic macula edema
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To evaluate the anatomical and visual outcomes of switching to intravitreal dexamethasone implant (IVD) in patients with diabetic macula edema unresponsive to 3 monthly consecutive intravitreal bevacizumab (IVB). Methods: This retrospective study included patients with diabetic macular edema (DME) who showed anatomically poor response to 3 consecutive IVB injections and were switched to IVD treatment in early period. In the study population best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded at baseline, and on months 3, 6, 9, and 12. Results: Overall, 27 eyes of 24 patients were included in our study. The mean age was 61.5 ± 9.5 years. The mean BCVA at baseline was 0.70 ± 0.21 LogMAR while the mean BCVA after 3 consecutive IVB injections was 0.69 ± 0.19 LogMAR. (p:0.83). The mean BCVA was 0.52 ± 0.21 LogMAR, 0.39 ± 0.22 LogMAR and 0.45 ± 0.27 LogMAR at 6, 9 and 12 months, respectively. (p=0.013, p=0.002, p<0.001). A statistically significant difference was observed for the mean BCVA at 6, 9 and 12 months compared to the mean BCVA at baseline and 3 months. The CMT was 522 ± 142 µm and decreased to 499 ± 152 µm at 3 months without statistical significance (p=0.51). After switching IVD, The mean CMT was 285 ± 40 µm, 278 ± 116 µm and 328 ± 172 µm at 6, 9 and 12 months, respectively (p<0.001, p<0.001, p<0.001). Conclusions: Better visual and anatomical results can be obtained with an early switch to IVD treatment in poorly responding DME.